中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2010年
9期
713-715
,共3页
张晓黎%程骁赬%叶娴%石晓菁
張曉黎%程驍赬%葉嫻%石曉菁
장효려%정효정%협한%석효정
白细胞介素11%血液肿瘤%血小板减少%化疗
白細胞介素11%血液腫瘤%血小闆減少%化療
백세포개소11%혈액종류%혈소판감소%화료
Interleukin-11%Hematologic neoplasms%Thrombocytopenia%Chemotherapy
目的 观察并评价低剂量白细胞介素11(IL-11)治疗恶性血液病化疗后血小板减少的临床疗效.方法 将70例化疗后伴血小板减少的恶性血液病(包括急性白血病、淋巴瘤、多发性骨髓瘤)患者随机分为治疗组和对照组,各35例.治疗组患者在化疗结束24 h后开始按50μg·kg-1·d-1剂量给予IL-11皮下注射,连续应用直至血小板数≥50×109/L.对照组患者化疗后则不予IL-11治疗.结果 治疗组血小板数恢复至≥50×109/L的平均时间为9.6 d,明显短于对照组(14.0 d,P＜0.05);血小板最低值平均为16.2×109/L,明显高于对照组(11.6×109/L,P＜0.05);血小板输注平均次数为2.88次,与对照组(2.98次)比较,差异无统计学意义(P＞0.05).治疗组中,有1例急性白血病患者诉心悸,有2例急性白血病和1例淋巴瘤患者出现畏寒、肌肉酸痛、乏力,但均能耐受.结论 应用IL-11治疗恶性血液病化疗后血小板减少,不仅能明显提高患者的血小板数和血小板最低水平,缩短血小板的恢复时间,而且不良反应轻微.
目的 觀察併評價低劑量白細胞介素11(IL-11)治療噁性血液病化療後血小闆減少的臨床療效.方法 將70例化療後伴血小闆減少的噁性血液病(包括急性白血病、淋巴瘤、多髮性骨髓瘤)患者隨機分為治療組和對照組,各35例.治療組患者在化療結束24 h後開始按50μg·kg-1·d-1劑量給予IL-11皮下註射,連續應用直至血小闆數≥50×109/L.對照組患者化療後則不予IL-11治療.結果 治療組血小闆數恢複至≥50×109/L的平均時間為9.6 d,明顯短于對照組(14.0 d,P＜0.05);血小闆最低值平均為16.2×109/L,明顯高于對照組(11.6×109/L,P＜0.05);血小闆輸註平均次數為2.88次,與對照組(2.98次)比較,差異無統計學意義(P＞0.05).治療組中,有1例急性白血病患者訴心悸,有2例急性白血病和1例淋巴瘤患者齣現畏寒、肌肉痠痛、乏力,但均能耐受.結論 應用IL-11治療噁性血液病化療後血小闆減少,不僅能明顯提高患者的血小闆數和血小闆最低水平,縮短血小闆的恢複時間,而且不良反應輕微.
목적 관찰병평개저제량백세포개소11(IL-11)치료악성혈액병화료후혈소판감소적림상료효.방법 장70례화료후반혈소판감소적악성혈액병(포괄급성백혈병、림파류、다발성골수류)환자수궤분위치료조화대조조,각35례.치료조환자재화료결속24 h후개시안50μg·kg-1·d-1제량급여IL-11피하주사,련속응용직지혈소판수≥50×109/L.대조조환자화료후칙불여IL-11치료.결과 치료조혈소판수회복지≥50×109/L적평균시간위9.6 d,명현단우대조조(14.0 d,P＜0.05);혈소판최저치평균위16.2×109/L,명현고우대조조(11.6×109/L,P＜0.05);혈소판수주평균차수위2.88차,여대조조(2.98차)비교,차이무통계학의의(P＞0.05).치료조중,유1례급성백혈병환자소심계,유2례급성백혈병화1례림파류환자출현외한、기육산통、핍력,단균능내수.결론 응용IL-11치료악성혈액병화료후혈소판감소,불부능명현제고환자적혈소판수화혈소판최저수평,축단혈소판적회복시간,이차불량반응경미.
Objective To investigate and evaluate the clinical therapeutic effect of low-dose interleukin-11 treatment of thrombocytopenia in patients with malignant hematologic diseases after chemotherapy. Methods 70 patients with hematologic malignancies including acute leukemia, lymphoma and multiple myeloma were randomly divided into treatment group (35 cases) and control group (35 cases)and were treated with chemotherapy. Cases in the treatment group received subcutaneous injection of control group were not administrated with interleukin-11. (50 μg·kg-1·d-1) until platelet counting recovered ≥50 × 109/L, while cases in the control group were not administrated with interleukin-11.Results The mean time of platelet recovery in the treatment group was 9.6 days, significantly shorter than that (14.0 days) in the control group (P ＜ 0. 05).The minimum platelet counting in the treatment group was significantly higher than that in the control group (16.2 × 109/L vs. 11.6 × 109/L, P ＜ 0.05). The mean times of platelet infusion after chemotherapy in the treatment group and control group were 2.88 and 2.98, respectively (P＞0.05). Conclusion Administration of interleukin-11 in thrombocytopenic patients with hematologic malignancies after chemotherapy may not only remarkably enhance platelet counts and shorten the recovery time of thrombocytopenia, but also has only mild side effects.
